Nov, 14 2018 13:30 JST

Source: Eisai

Eisai Receives "IR Grand Prix Award"

TOKYO, Nov, 14 2018 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received the "IR Grand Prix Award" at the IR Award 2018 held by the Japan Investor Relations Association (JIRA). This marks the second time that Eisai has received the IR Grand Prix Award following 2006. Including the receipt of Best IR Awards in 2004, 2005, 2009 and 2012, this is the 6th time Eisai has received an IR Award, and Eisai is the first pharmaceutical company to receive two IR Grand Prix Awards.

The IR Award (Committee Chairman: Tetsuo Kitagawa, Professor of International Management, Aoyama Gakuin University Graduate School) is designed to recognize companies which have been highly accredited in the investment community for their understanding and promotion of IR activities, and this year marks the 23rd year since the start of the IR Awards. 299 companies applied for the IR Award 2018, and after surveys and screenings by select committee members, Eisai was the sole company selected for the IR Grand Prix Award this year.

The reasons for Eisai's selection are as follows:
"Eisai is proactively disclosing information and constantly raising the level of disclosure. For many years, top management has been engaged in dialogue with investors, candidly discussing the company's longer-term vision and management issues. Eisai's CFO and IR Department have been enhancing the presentation of balance sheet management and disclosure of non-financial information ahead of other companies. In terms of ESG-related efforts, Eisai not only discloses information but also holds meetings with presentations by outside directors and meetings to explain its integrated report. The company's timeliness and fairness in disclosure is highly regarded, evidenced by its timely disclosure of information that may affect operating performance and prompt holding of briefings on such matters."

Furthermore, in celebration of the 25th year since the establishment of the JIRA, as part of the "JIRA 25th Anniversary Commemorative Award" which seeks to specially recognize companies which have continued IR activities over the long term and have produced outstanding achievements in appropriate information disclosure and constructive dialogue with investors and shareholders, Eisai was selected as both a "Company with Greatest Improvement in IR" and as a "Company with Best Continual Efforts in IR." For further details, please visit the JIRA website:

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Together with strengthening its ESG initiatives in order to realize this corporate philosophy, Eisai respects the rights of shareholders and investors, ensures fairness and transparency in management, and works on its IR activities to aid the enhancement of corporate value.

About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit

Public Relations Department,
Eisai Co., Ltd.
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai to Refresh and Launch Sahne Cream After 20 Years with Mild Scent and New Package
August 01 2019 10:41 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA
July 23 2019 11:37 JST
Eisai Presented Latest Trends of Treatment for Alzheimer's at AAIC 2019
July 19 2019 12:00 JST
Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
July 19 2019 08:15 JST
Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019
July 18 2019 13:26 JST
Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019
July 18 2019 12:01 JST
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
July 17 2019 08:20 JST
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
July 11 2019 12:59 JST
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
July 11 2019 09:04 JST
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts
July 10 2019 12:27 JST
More Press release >>

Latest Press Release

More Latest Release >>